 Natalizumab
"Natalizumab" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A humanized monoclonal immunoglobulin G4 antibody to human INTEGRIN ALPHA4 that binds to the alpha4 subunit of INTEGRIN ALPHA4BETA1 and integrin alpha4beta7. It is used as an IMMUNOLOGIC FACTOR in the treatment of RELAPSING-REMITTING MULTIPLE SCLEROSIS and CROHN'S DISEASE.
| Descriptor ID |
D000069442
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060.813 D12.776.124.790.651.114.224.060.813 D12.776.377.715.548.114.224.200.813
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Natalizumab".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Natalizumab [D12.776.124.486.485.114.224.060.813]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Natalizumab [D12.776.124.790.651.114.224.060.813]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
- Natalizumab [D12.776.377.715.548.114.224.200.813]
Below are MeSH descriptors whose meaning is more specific than "Natalizumab".
This graph shows the total number of publications written about "Natalizumab" by people in this website by year, and whether "Natalizumab" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 0 | 2 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2010 | 0 | 5 | 5 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 2 | 2 | | 2013 | 0 | 1 | 1 | | 2015 | 3 | 0 | 3 | | 2017 | 1 | 0 | 1 | | 2018 | 2 | 0 | 2 | | 2019 | 0 | 2 | 2 | | 2020 | 3 | 0 | 3 | | 2021 | 0 | 1 | 1 | | 2023 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Natalizumab" by people in Profiles.
-
Alvarez E, Nair KV, Tan H, Rathi K, Gabler NB, Maiese EM, Deshpande C, Shao Q. Real-world cost of care and site of care in patients with multiple sclerosis initiating infused disease-modifying therapies. J Med Econ. 2023 Jan-Dec; 26(1):494-502.
-
Alvarez E, Nair KV, Hoyt BD, Seale RA, Sillau S, Miravalle A, Engebretson E, Schurr B, Corboy JR, Vollmer TL, Honce JM. Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Mult Scler Relat Disord. 2021 Oct; 55:103170.
-
Kowarik MC, Astling D, Lepennetier G, Ritchie A, Hemmer B, Owens GP, Bennett JL. Differential Effects of Fingolimod and Natalizumab on B Cell Repertoires in Multiple Sclerosis Patients. Neurotherapeutics. 2021 01; 18(1):364-377.
-
Vollmer BL, Nair K, Sillau S, Corboy JR, Vollmer T, Alvarez E. Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2020 09; 7(9):1466-1476.
-
Rempe T, Wang Q, Wu Q, Ballur Narayana Reddy V, Newcomer Z, Miravalle A, Mao-Draayer Y. Progressive multifocal leukoencephalopathy and granule cell neuronopathy with novel mutation flanking VP1 C-terminus in natalizumab-extended interval dosing. Neurol Neuroimmunol Neuroinflamm. 2020 05 04; 7(3).
-
Clifford DB, Tyler KL. Dosing interval of natalizumab in MS: Do good things come to those who wait? Neurology. 2019 10 08; 93(15):655-656.
-
Gross RH, Corboy JR. Monitoring, Switching, and Stopping Multiple Sclerosis Disease-Modifying Therapies. Continuum (Minneap Minn). 2019 Jun; 25(3):715-735.
-
Vollmer BL, Nair KV, Sillau S, Corboy JR, Vollmer T, Alvarez E. Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment. Ann Clin Transl Neurol. 2019 02; 6(2):252-262.
-
Vollmer B, Honce JM, Sillau S, Corboy JR, Vollmer T, Nair K, Alvarez E. The impact of very short transition times on switching from Natalizumab to Fingolimod on imaging and clinical effectiveness outcomes in multiple sclerosis. J Neurol Sci. 2018 07 15; 390:89-93.
-
Evan JR, Bozkurt SB, Thomas NC, Bagnato F. Alemtuzumab for the treatment of multiple sclerosis. Expert Opin Biol Ther. 2018 03; 18(3):323-334.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|